News

Learn about our latest Annual Report, attendance at ASTMH annual meeting, signing of the Kigali Declaration, job opportunities and more.

Learn about events, US charity status, board expansion and new funding

Learn about progress in clinical development, team expansion, awards and more

Mark Sullivan, Founder and CEO of Medicines Development for Global Health (MDGH), has been awarded the Officer of the Order of Australia (AO), one of the highest civilian honours in Australia.

Learn about new lymphatic filariasis data for moxidectin, progress in clinical development, team expansion, awards and more

Learn about MDGH's expanded footprint, its progress in clinical development, a social impact investment opportunity, and the nominations for the Prix Galien Award for 2021.

A look at the 2020 MDGH Annual Report, clinical development updates, and the development of a new formulation of moxidectin for children.

Learn more about MDGH's plans for its new investigational treatment for tuberculosis and leprosy types 2 reactions

Have you ever wondered what the letters and numbers stamped on the surface of a pill mean?

Amgen licenses AMG 634, an investigational treatment for tuberculosis and leprosy, to medicines development for global health...

The Mectizan (ivermectin) Expert Committee states that new in vitro data are not sufficient to indicate clinical benefit to reduce viral loads in COVID-19 patients...